前庭神经鞘瘤的药物治疗前景

钟平

doi:10.12182/20220760202

栏目: 专家笔谈

前庭神经鞘瘤的药物治疗前景

doi:

钟平^{1, 2, 3, 4,}

1. 清华综合大学其他华山医疗机构神经系统产科（成都 200040）
2. 国家的运动神经病医学专业重心（苏州 200040）
3. 昆明市脑能力转变及脑神经净化重心科学试验室（昆明 200040）
4. 复旦高校高校周围神经整形外科研究探讨所（北京 200040）

基金项目: 中国医学科学院医学与健康科技创新工程（No. 2019-I2M-5-008）和上海申康医院发展中心临床三年行动计划（No. SHDC2020CR1049B）资助

计量
- 文章访问数: 1
- HTML全文浏览量: 0
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-09
- 修回日期: 2023-07-09
- 刊出日期: 2023-07-22

Prospects of Drug Therapy of Vestibular Schwannoma

ZHONG Ping^{1, 2, 3, 4
,}

1. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
2. National Center for Neurological Disorders, Shanghai 200040, China
3. Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai 200040, China
4. Neurosurgical Institute, Fudan University, Shanghai 200040, China

摘要

摘要: 前庭神经鞘瘤（vestibular schwannoma, VS）是中枢神经系统最常见的良性肿瘤之一。目前主要采用手术治疗、立体定向放射治疗及随访观察等，缺少可用于VS的药物治疗。虽然手术技术相对成熟，但并发症无法完全避免；且不同病例生长速度迥异，对放射治疗的敏感性也存在较大差异。随着分子生物学研究的不断深入，VS的生长机制研究大多聚焦于神经纤维蛋白2基因（neurofibromin 2, NF2）和merlin蛋白的相关上下游和受体蛋白酪氨酸激酶（receptor protein tyrosine kinase, RTK）、血管内皮生长因子受体（vascular endothelial growth factor receptor, VEGFR）、雷帕霉素靶蛋白复合物1（mammalian target of rapamycin complex 1, mTORC1）、血小板衍生生长因子受体（platelet derived growth factor receptor, PDGFR）等相应靶点。已报道的研究提示有相当多的药物对VS细胞的增殖都有抑制作用。虽然大部分研究都还在体外细胞实验和/或动物实验阶段，少部分进入临床Ⅰ～Ⅱ期研究，尚不能导向临床治疗；但据此可以全面了解VS药物治疗的现状和前景，有助于后续研究的开展。
- 前庭神经鞘瘤 /
- koko体育app: 药物治疗 /
- koko体育app: 治疗靶点
Abstract: Vestibular schwannoma (VS) is one of the most common types of benign tumors of the central nervous system. At present, the prevailing treatment methods of VS include surgery, stereotactic radiotherapy, and follow-up observation, etc. However, there is still no drug therapy available for treating VS. Although the surgical technique is relatively mature, the complications cannot be completely avoided. Furthermore, both the growth rate of different cases and patients’ sensitivity to radiotherapy vary greatly. With the constant progress made in molecular biology research, most of the studies on the growth mechanism of VS focus on the upstream and downstream of neurofibromin 2 (NF2) gene and merlin protein, and a number of corresponding targets, including receptor protein tyrosine kinase (RTK), vascular endothelial growth factor receptor (VEGFR), mammalian target of rapamycin complex 1 (mTORC1) and platelet derived growth factor receptor (PDGFR). It has been reported in some studies that quite a few drugs could inhibit the proliferation of VS cells. Most of the studies are still in the stage of in vitro cell experiment and/or animal experiment. A small number of studies have entered phase Ⅰ and phase Ⅱ clinical trials, but have not led to any clinical treatment yet. This paper provides a comprehensive understanding of the current status and the prospects of drug therapies of VS, which is conducive to the development of subsequent research.
- koko体育app: Vestibular schwannomas /
- koko体育app: Drug therapy /
- koko体育app: Therapeutic targets

koko体育app: HTML全文

参考文献(33)

[1]	HUANG X, XU J, ZHONG P. The clinical feature of intracranial vestibular Schwannomas--A retrospective review of 1009 vestibular schwannomas in single hospital. Acta Neurochirurgical,2011,Suppl 53: 1833–1905.
[2]	ASTHAGIRI A R, PARRY D M, BUTMAN J A, et al. Neurofibromatosis type 2. Lancet,2009,373(9679): 1974–1986. doi:
[3]	HUANG X, XU J, XU M, et al. Functional outcome and complications after the microsurgical removal of giant vestibular schwannomas via the retrosigmoid approach: A retrospective review of 16-year experience in a single hospital. BMC Neurol, 2017, 17: 18[2023-04-17]. .
[4]	HUANG X, XU M, XU J, et al. Complications and management of large intracranial vestibular Schwannomas via the retrosigmoid approach. World Neurosurg,2017,99: 326–335. doi:
[5]	LONG J F, ZHANG Y, HUANG X, et al. A review of drug therapy in vestibular Schwannoma. Drug Des Devel Ther,2021,15: 75–85. doi:
[6]	ZHANG Y, LONG J F, REN J W, et al. Potential molecular biomarkers of vestibular Schwannoma growth: Progress and prospects. Front Oncol, 2021, 11: 731441[2023-04-17]. .
[7]	ROBINSON D R, WU Y M, LIN S F. The protein tyrosine kinase family of the human genome. Oncogene,2000,19(49): 5548–5557. doi:
[8]	CIARK J J, PROVENZANO M, DIGGELMANN H R, et al. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular Schwannoma xenografts in nude mice: A preliminary study. Otol Neurotol,2008,29(6): 846–853. doi:
[9]	KARAJANNIS M A, LEGAULT G, HAGIWARA M, et al. Phase Ⅱ trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular Schwannomas. Neuro Oncol,2012,14(9): 1163–1170. doi:
[10]	ALTUNA X, LOPEZ J P, YU M, et al. Potential role of imatinib mesylate (gleevec, STI-571) in the treatment of vestibular Schwannoma. Otol Neurotol,2011,32(1): 163–170. doi:
[11]	MUKHERJEE J, KAMNASARAN D, BALASUBRAMANIAM A, et al. Human Schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by gleevec (imatinib mesylate). Cancer Res,2009,69(12): 5099–5107. doi:
[12]	AMMOUN S, SCHMID M C, TRINER J, et al. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol,2011,13(7): 759–766. doi:
[13]	SABHA N, AU K, AGNIHOTRI S, et al. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS One, 2012, 7(6): 10[2023-04-17]. .
[14]	PETRILLI A M, GARCIA J, BOTT M, et al. Ponatinib promotes a G₁ cell-cycle arrest of merlin/NF2-deficient human Schwann cells. Oncotarget,2017,8(19): 31666–31681. doi:
[15]	ACEVEDO L M, BARILLAS S, WEIS S M, et al. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood,2008,111(5): 2674–2680. doi:
[16]	PLOTKIN S R, STEMMER-RACHAMIMOV A O, BARKER F G, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. New Engl J Med,2009,361(4): 358–367. doi:
[17]	PLOTKIN S R, DUDA D G, MUZIKANSKY A, et al. Multicenter, prospective, phase Ⅱ and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol,2019,37(35): 3446–3454. doi:
[18]	GUGEL I, KLUWE L, ZIPFEL J, et al. Minimal effect of bevacizumab treatment on residual vestibular schwannomas after partial resection in young neurofibromatosis type 2 patients. Cancers, 2019, 11 (12): 1862[2023-04-17]. .
[19]	SLUSARZ K M, MERKER V L, MUZIKANSKY A, et al. Long-term toxicity of bevacizumab therapy in neurofibromatosis2 patients. Cancer Chemother Pharmacol,2014,73(6): 1197–1204. doi:
[20]	RIINA H A, BURKHARDT J K, SANTILLAN A, et al. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of bevacizumab for the treatment of vestibular Schwannomas in neurofibromatosis type 2. Interv Neuroradiol,2012,18(2): 127–132. doi:
[21]	KARAJANNIS M A, HAGIWARA M, SCHREYER M, et al. Sustained imaging response and hearing preservation with low-dose beva-cizumab in sporadic vestibular Schwannoma. Neuro Oncol,2019,21(6): 822–824. doi:
[22]	TROUTMAN S, MOLEIRINHO S, KOTA S, et al. Crizotinib inhibits NF2-associated Schwannoma through inhibition of focal adhesion kinase 1. Oncotarget,2016,7(34): 54515–54525. doi:
[23]	WELLING D B, LASAK J M, AKHMAMETYEVA E, et al. cDNA microarray analysis of vestibular Schwannomas. Otol Neurotol,2002,23(5): 736–748. doi:
[24]	LEE T X, PACKER M D, HUANG J, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant Schwannoma cells. Eur J Cancer,2009,45(9): 1709–1720. doi:
[25]	BUSH M L, OBLINGER J, BRENDEL V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular Schwannomas and meningiomas. Neuro Oncol,2011,13(9): 983–999. doi:
[26]	JACOB A, OBLINGER J, BUSH M L, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular Schwannomas. Laryngoscope,2012,122(1): 174–189. doi:
[27]	JAMES M F, STIVISON E, BEAUCHAMP R, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res,2012,10(5): 649–659. doi:
[28]	GIOVANNINI M, BONNE N X, VITTE J, et al. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol,2014,16(4): 493–504. doi:
[29]	KARAJANNIS M A, LEGAULT G, HAGIWARA M, et al. Phase Ⅱ study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular Schwannomas. Neuro Oncol,2014,16(2): 292–297. doi:
[30]	SONAM D, DANIEL R, STANKOVIC K M. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and Schwann cells. Cancer Biol Ther,2015,16(1): 170–175. doi:
[31]	KANDATHIL C K, DILWALI S, WU C, et al. Aspirin intake correlates with halted growth of sporadic vestibular Schwannomain vivo. Otol Neurotol,2014,35(2): 353–357. doi:
[32]	SAGERS J E, BROWN A S, VASILIJIC S, et al. Publisher correction: Computational repositioning and preclinical validation of mifepristone for human vestibular Schwannoma. Sci Rep, 2018, 8 (1): 17449[2023-04-17]. .
[33]	OUERDANI A, GOUTAGNY S, KALAMARIDES M, et al. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular Schwannomas of patients with neurofibromatosis type 2. Cancer Chemother Pharmacol,2016,77(6): 1263–1273. doi: